Clinical Trials on Chiari Malformation Type I in Canada

Total 117 results

Centre hospitalier de l'Université de Montréal...

Active, not recruiting

Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations (TATAM)

Unruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | Arteriovenous Malformations, Cerebral

Canada, France
Centre hospitalier de l'Université de Montréal...
Centre Hospitalier Régional et Universitaire de Brest

Recruiting

Treatment of Brain AVMs (TOBAS) Study (TOBAS)

Arteriovenous Malformations | Unruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | AVM | BAVM

France, United States, Canada, Brazil, Chile, Colombia
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
University Health Network, Toronto

Recruiting

Pilot Study on Trametinib for Surgical Unruptured AVMs (OZUHN-017)

Arteriovenous Malformations

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
Ottawa Hospital Research Institute

Recruiting

Evaluation of Susceptibility-weighted Magnetic Resonance Imaging and 4d-time-resolved Magnetic Resonance Angiography in Brain Arteriovenous Malformations

Arteriovenous Malformations

Canada
Unity Health Toronto

Completed

Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy

Pulmonary Arteriovenous Malformations

Canada
University Health Network, Toronto

Completed

Hippocampal Radiation Exposure and Memory

Trigeminal Neuralgia | Schwannoma | Arteriovenous Malformation

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
University of British Columbia

Terminated

Treatment of Type I Supracondylar Fractures of the Humerus

Type I Supracondylar Fracture of the Humerus

Canada
Centre hospitalier de l'Université de Montréal...
Maisonneuve-Rosemont Hospital

Recruiting

Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting (CXL-KPro)

Corneal Melting in Boston Keratoprosthesis Type I

Canada
Marie-Claude Robert
Fonds de recherche en ophtalmologie de l'Université de Montréal

Completed

Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers

Corneal Blindness | Boston Keratoprosthesis Type I Candidate

Canada
University of Alberta
Sernova Corp

Terminated

A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation

Type I Diabetes

Canada
University of California, Los Angeles
Université de Montréal

Withdrawn

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

Stroke | Epilepsy | Tuberous Sclerosis | Sturge-Weber Syndrome | Focal Cortical Dysplasia | Hemimegalencephaly | Polymicrogyria | Rasmussen Encephalitis | Gliosis | Tumor, Brain

United States, Canada
National Tuberous Sclerosis Association

Recruiting

TSC Biosample Repository and Natural History Database

Tuberous Sclerosis | Lymphangioleiomyomatosis

United States, Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
GRIN Therapeutics, Inc.

Recruiting

A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Tuberous Sclerosis Complex | Focal Cortical Dysplasia

Spain, United Kingdom, Australia, Belgium, Canada, Italy, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (EXIST-1)

Tuberous Sclerosis | Subependymal Giant Cell Astrocytoma

United States, Belgium, Canada, Germany, Italy, Russian Federation, Netherlands, Poland, Australia, United Kingdom
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

A Randomized Trial of Unruptured Brain AVMs (ARUBA)

Arteriovenous Malformations, Cerebral

United States, Brazil, Canada, Australia, Austria, Finland, France, Germany, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Marinus Pharmaceuticals

Enrolling by invitation

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Tuberous Sclerosis Complex

United States, Spain, United Kingdom, China, Italy, France, Israel, Germany, Canada, Australia
University of Manitoba
Co-Investigator - Dr. Cheryl Rockman-Greenberg

Completed

Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial (Glycosade GSD)

Hypoglycemia | Glycogen Storage Disorder Type 1 | Cornstarch | Glycosade

Canada
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
Amsterdam Molecular Therapeutics
ICON plc

Terminated

Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies

Hyperlipoproteinemia Type I

Canada
Marinus Pharmaceuticals

Active, not recruiting

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy (TrustTSC)

Tuberous Sclerosis Complex

United States, Spain, United Kingdom, Israel, Italy, Germany, France, Canada
Université de Sherbrooke
Institut de Recherches Cliniques de Montreal

Recruiting

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency (AGL12)

Lipoprotein Lipase Deficiency

Canada
Amsterdam Molecular Therapeutics
The Clinical Trial Company

Completed

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Familial Lipoprotein Lipase Deficiency

Canada
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
Amsterdam Molecular Therapeutics
International Antiviral Therapy Evaluation Center

Unknown

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Familial Lipoprotein Lipase Deficiency

Canada
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Longitudinal Studies of Brain Structure and Function in MPS Disorders

Mucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VII

United States, Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

Canada
Amsterdam Molecular Therapeutics
The Clinical Trial Company

Unknown

Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies

Lipoprotein Lipase Deficiency

Canada
Ottawa Hospital Research Institute
Canadian Diabetes Association

Completed

The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy (AWARE)

Diabetes Mellitus | Chronic Pain | Diabetic Peripheral Neuropathy | Type I Diabetes | Type II Diabetes

Canada
Novartis Pharmaceuticals

Terminated

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

South Africa, Germany, United Kingdom, France, United States, Canada, Netherlands
UniQure Biopharma B.V.
Chiesi Farmaceutici S.p.A.

Withdrawn

Alipogene Tiparvovec for the Treatment of LPLD Patients

LPL Deficiency

Canada, United States
University Health Network, Toronto

Recruiting

Virtual Rehabilitation for Cancer Survivors

Lymphoma | Lymphoproliferative Disorders | Breast Cancer Stage I | Breast Cancer Stage II | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Breast Cancer Stage III | Colorectal Cancer Stage I | Head and Neck Cancer Stage III | Breast Cancer, Stage 0 | Head and Neck Cancer Stage I | Head and Neck Cancer...

Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Hypertriglyceridemia | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency, Familial | Chylomicronemia, Familial

Canada
Allergy Therapeutics

Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Terminated

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
University Health Network, Toronto
Ontario Ministry of Health and Long Term Care; Canadian Cancer Society (CCS)

Recruiting

Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer (AS-PTC)

Thyroid Cancer Stage I

Canada
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Ultragenyx Pharmaceutical Inc

Active, not recruiting

Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia

Glycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)

Netherlands, United States, Canada, Spain

Clinical Trials on Chiari Malformation Type I in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations